153 related articles for article (PubMed ID: 22942707)
1. Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.
Abudukadeer A; Bakry R; Goebel G; Mutz-Dehbalaie I; Widschwendter A; Bonn GK; Fiegl H
Int J Mol Sci; 2012; 13(7):8353-8363. PubMed ID: 22942707
[TBL] [Abstract][Full Text] [Related]
2. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.
Qian ZR; Sano T; Yoshimoto K; Asa SL; Yamada S; Mizusawa N; Kudo E
Mod Pathol; 2007 Dec; 20(12):1269-77. PubMed ID: 17873891
[TBL] [Abstract][Full Text] [Related]
4. Prognostic DNA methylation marker in serum of cancer patients.
Müller HM; Fiegl H; Widschwendter A; Widschwendter M
Ann N Y Acad Sci; 2004 Jun; 1022():44-9. PubMed ID: 15251938
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix.
Missaoui N; Hmissa S; Trabelsi A; Traoré C; Mokni M; Dante R; Frappart L
Pathol Res Pract; 2011 Jan; 207(1):37-42. PubMed ID: 21129853
[TBL] [Abstract][Full Text] [Related]
6. CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis.
Liu G
Future Oncol; 2018 Jan; 14(1):51-63. PubMed ID: 29237293
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
Yang J; Niu H; Huang Y; Yang K
PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
Lin YL; Xie PG; Ma JG
Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
[TBL] [Abstract][Full Text] [Related]
12. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.
Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H
Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.
Zhu C; Feng X; Ye G; Huang T
Medicine (Baltimore); 2017 Apr; 96(16):e6650. PubMed ID: 28422868
[TBL] [Abstract][Full Text] [Related]
14. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
15. CDH1 and SNAI1 are regulated by E7 from human papillomavirus types 16 and 18.
Rosendo-Chalma P; Antonio-Vejar V; Bigoni-Ordóñez GD; Patiño-Morales CC; Cano-García A; García-Carrancá A
Int J Oncol; 2020 Jul; 57(1):301-313. PubMed ID: 32319591
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation in serum and tumors of cervical cancer patients.
Widschwendter A; Müller HM; Fiegl H; Ivarsson L; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Clin Cancer Res; 2004 Jan; 10(2):565-71. PubMed ID: 14760078
[TBL] [Abstract][Full Text] [Related]
17. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
18. Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma.
Attaleb M; El hamadani W; Khyatti M; Benbacer L; Benchekroun N; Benider A; Amrani M; El Mzibri M
Oncol Res; 2009; 18(4):185-92. PubMed ID: 20112504
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma.
Yi TZ; Guo J; Zhou L; Chen X; Mi RR; Qu QX; Zheng JH; Zhai L
Cancer Invest; 2011 Jan; 29(1):86-92. PubMed ID: 20874004
[TBL] [Abstract][Full Text] [Related]
20. Methylation pattern of CDH13 gene in digestive tract cancers.
Hibi K; Kodera Y; Ito K; Akiyama S; Nakao A
Br J Cancer; 2004 Sep; 91(6):1139-42. PubMed ID: 15292927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
